{"id":12354,"date":"2019-01-04T11:36:27","date_gmt":"2019-01-04T16:36:27","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12354"},"modified":"2019-01-04T11:36:27","modified_gmt":"2019-01-04T16:36:27","slug":"bristol-myers-squibb-will-acquire-celgene-in-blockbuster-74b-deal","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12354","title":{"rendered":"Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal"},"content":{"rendered":"<p>(By Adam Feurerstein and Matthew Herper for ST<em>A<\/em>T)<\/p>\n<p class=\"danger-zone\"><span class=\"big-cap-wrap\"><span class=\"big-cap\">I<\/span><\/span>n a blockbuster deal between two of biopharma\u2019s largest players, Bristol-Myers Squibb said Thursday it plans to buy Celgene for $74 billion.\u00a0 <a href=\"https:\/\/www.statnews.com\/2019\/01\/03\/bristol-myers-to-acquire-celgene\/\">Continue reading article here&#8230;<\/a><\/p>\n<p class=\"danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p class=\"danger-zone\">\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Adam Feurerstein and Matthew Herper for STAT) In a blockbuster deal between two of biopharma\u2019s largest players, Bristol-Myers Squibb<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-12354","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12354"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12354\/revisions"}],"predecessor-version":[{"id":12355,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12354\/revisions\/12355"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}